Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • PMN310 | Amyloid-Beta
    • PMN267 | TDP-43
    • PMN442 | Alpha-Synuclein
    • Vaccines
    • Posters & Publications
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Nov 13, 2019

ProMIS Neurosciences Undertaking $6.5M Private Placement

Nov 7, 2019

ProMIS Neurosciences Outlines Best-in-class Approach to Amyloid-beta-targeting Drug Candidates for Alzheimer’s Disease

Nov 7, 2019

ProMIS Neurosciences outlines best-in-class approach to amyloid-beta-targeting drug candidates for Alzheimer's disease

Oct 24, 2019

ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's disease

Oct 23, 2019

ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43

Oct 17, 2019

ProMIS Neurosciences advances Alzheimer’s disease program targeting neurotoxic forms of tau

Oct 17, 2019

ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxic forms of tau

Oct 8, 2019

ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy

Sep 16, 2019

ProMIS Neurosciences Executive Chairman Eugene Williams to Speak on Panel at Fall Investor Summit

Sep 3, 2019

ProMIS Neurosciences to Present at H.C. Wainwright Investor Conference

  • arrow_back
  • 1…
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • …27
  • arrow_forward
Facebook Linkedin Spotify Twitter
©2026 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy